PHILEOS (


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
13 01 2021
Historique:
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 15 5 2021
Statut: epublish

Résumé

Two meta-analyses showed lower bone mineral density (BMD) in patients with haemophilia (haemophilia type and severity were often not specified) compared with healthy controls. This finding could be related to reduced mobility and sedentary lifestyle, and/or hepatitis C or HIV infection. The aim of this study is to determine osteoporosis prevalence in patients with haemophilia classified in function of the disease type (A or B) and severity, and to evaluate the potential role of regular prophylactic factor replacement (early vs delayed initiation) in preserving or restoring BMD. The haemoPHILia and ostEoporOSis Study is a prospective, controlled, multicentre study that will include patients in France (13 haemophilia treatment centres), Belgium (1 centre) and Romania (1 centre). In total, 240 patients with haemophilia and 240 matched healthy controls will be recruited (1:1). The primary objective is to determine osteoporosis prevalence in patients with severe haemophilia A and B (HA and HB) without prophylaxis, compared with healthy controls. Secondary outcomes include: prevalence of osteoporosis and osteopenia in patients with mild, moderate and severe HA or HB with prophylaxis (grouped in function of their age at prophylaxis initiation), compared with healthy subjects; BMD in patients with HA and HB of comparable severity; correlation between BMD and basal factor VIII/IX levels and thrombin potential; and quantification of plasmatic markers of bone remodelling (formation and resorption) in patients with haemophilia. The protocol was approved by the French Ethics Committee and by the French National Agency for Medicines and Health Products Safety (number: 2019-A03358-49). The results of this study will be actively disseminated through scientific publications and conference presentations. NCT04384341.

Identifiants

pubmed: 33441362
pii: bmjopen-2020-042283
doi: 10.1136/bmjopen-2020-042283
pmc: PMC7812091
doi:

Banques de données

ClinicalTrials.gov
['NCT04384341']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e042283

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Indian J Hematol Blood Transfus. 2014 Dec;30(4):351-5
pubmed: 25435741
Thromb Haemost. 2012 Mar;107(3):545-51
pubmed: 22318743
Eur J Epidemiol. 2009;24(6):321-8
pubmed: 19296062
Thromb Haemost. 2010 Mar;103(3):596-603
pubmed: 20076854
Haemophilia. 2009 Mar;15(2):559-65
pubmed: 19187193
Haemophilia. 2015 Jan;21(1):109-15
pubmed: 25382849
Bone. 2009 May;44(5):813-21
pubmed: 19442625
Am J Hematol. 2016 Dec;91(12):1252-1260
pubmed: 27563744
Haemophilia. 2018 Jul;24(4):e222-e229
pubmed: 29902356
Liver Int. 2018 May;38(5):776-785
pubmed: 29479832
J Am Osteopath Assoc. 2019 Jun 1;119(6):357-363
pubmed: 31135863
World Health Organ Tech Rep Ser. 2003;921:1-164, back cover
pubmed: 15293701
Haemophilia. 2009 Jan;15(1):261-6
pubmed: 19149852
Haemophilia. 2018 Nov;24(6):980-987
pubmed: 30273987
Q J Med. 1994 Mar;87(3):181-6
pubmed: 8208906
Curr Opin HIV AIDS. 2016 May;11(3):301-5
pubmed: 26882459
Osteoporos Int. 2014 Oct;25(10):2399-407
pubmed: 25001982
J Biol Chem. 2009 Nov 13;284(46):31704-13
pubmed: 19758994
Haemophilia. 2011 Sep;17(5):e870-6
pubmed: 21435116
Haemophilia. 2014 Jan;20(1):121-8
pubmed: 23902277
Br J Oral Maxillofac Surg. 2010 Dec;48(8):633-6
pubmed: 20018416
Haemophilia. 2020 Mar;26(2):325-332
pubmed: 31884718

Auteurs

Brigitte Tardy-Poncet (B)

Inserm CIC 1408, Saint-Etienne University Hospital Center, Saint-Etienne, Rhône-Alpes, France brigitte.tardy@chu-st-etienne.fr.
Hemophilia Treatment Center, Saint-Etienne University Hospital Center, Saint-Etienne, Rhône-Alpes, France.
Inserm U1059, Sainbiose, University of Lyon, Saint-Etienne, Auvergne-Rhône-Alpes, France.

Barbara Play (B)

Regional Medical Coagulation & Intensive Care, CSL Behring SA, Paris, Île-de-France, France.

Aurélie Montmartin (A)

Inserm U1059, Sainbiose, University of Lyon, Saint-Etienne, Auvergne-Rhône-Alpes, France.

Pauline Damien (P)

Inserm CIC 1408, Saint-Etienne University Hospital Center, Saint-Etienne, Rhône-Alpes, France.

Edouard Ollier (E)

Clinical Research Unit Innovation and Pharmacology, Saint-Etienne University Hospital Center, Saint-Etienne, Rhône-Alpes, France.

Emilie Presles (E)

Inserm CIC 1408, Saint-Etienne University Hospital Center, Saint-Etienne, Rhône-Alpes, France.
Clinical Research Unit Innovation and Pharmacology, Saint-Etienne University Hospital Center, Saint-Etienne, Rhône-Alpes, France.

Arnauld Garcin (A)

Clinical Research Unit Innovation and Pharmacology, Saint-Etienne University Hospital Center, Saint-Etienne, Rhône-Alpes, France.

Bernard Tardy (B)

Inserm CIC 1408, Saint-Etienne University Hospital Center, Saint-Etienne, Rhône-Alpes, France.
Inserm U1059, Sainbiose, University of Lyon, Saint-Etienne, Auvergne-Rhône-Alpes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH